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Introduction: Breast cancer is a devastating disease that results in approximately 40,000 deaths each year in the
USA. Current drug screening and chemopreventatitive methods are suboptimal, due in part to the poor specificity
of compounds for cancer cells. Poly (ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi)-mediated therapy is a
promising approach for familial breast cancers caused by mutations of breast cancer-associated gene-1 and -2
(BRCA1/2), yet drug resistance frequently occurs during the treatment. Moreover, PARPis exhibit very little effect
on cancers that are proficient for DNA repair and clinical efficacy for PARPis as single-agent therapies has yet to
be illustrated.
Methods: Using a quantitative high-throughput screening approach, we screened a library containing 2,816 drugs,
most of which are approved for human or animal use by the Food and Drug Administration (FDA) or other
countries, to identify compounds that sensitize breast cancer cells to PARPi. After initial screening, we performed
further cellular and molecular analysis on lestaurtinib, which is an orally bioavailable multikinase inhibitor and has
been used in clinical trials for myeloproliferative disorders and acute myelogenous leukemia.
Results: Our study indicated that lestaurtinib is highly potent against breast cancers as a mono-treatment agent.
It also strongly enhanced the activity of the potent PARPi AG14361 on breast cancer cell growth both in vitro and
in vivo conditions. The inhibition of cancer growth is measured by increased apoptosis and reduced cell proliferation.
Consistent with this, the treatment results in activation of caspase 3/7, and accumulation of cells in the G2 phase
of the cell cycle, irrespective of their BRCA1 status. Finally, we demonstrated that AG14361 inhibits NF-κB signaling,
which is further enhanced by lestaurtinib treatment.
Conclusions: Lestaurtinib amplifies the ability of the PARP1 inhibitor AG14361 to kill BRCA1 mutant and wild-type breast
cancer cells, at least in part, by inhibiting NF-κB signaling. Each of these drugs has been approved for clinical trials for
several different cancers, thus, their combination treatment should be applicable for a breast cancer trial in the future.* Correspondence: chuxiad@mail.nih.gov
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Breast cancer is one of the most prevalent cancers in
women worldwide and it is estimated that a million
women will develop this disorder each year. About 8% of
breast cancer cases are inheritable, associated with mu-
tations of highly penetrant breast cancer susceptibility
genes, such as breast cancer-associated gene-1 and -2
(BRCA1/2) and other tumor suppressor genes [1-7]. In
addition, it has been estimated that BRCA1 mutation
carriers have a 50 to 80% risk of developing breast
cancer before the age of 70 years [8-11].
Both BRCA1 and BRCA2 play essential roles in many
biological processes [12-17]. A common feature of BRCA1/
2-associated tumorigenesis is massive genetic instability,
primarily due to the fact that cells lacking BRCA1 or
BRCA2 have impaired ability to undergo homologous
recombination (HR) [15,16,18,19], therefore these cells
cannot effectively repair HR-mediated DNA damage,
including DNA double-strand breaks (DSBs). The genetic
instability often leads to altered expression of many genes
and signaling pathways making it difficult to inhibit tu-
morigenesis and progression by targeting a single mo-
lecular target. Recently, significant work in the area of
synthetic lethality has led to new approaches for the treat-
ment of BRCA1/2-deficient cancers using high efficacy poly
(ADP-ribose) polymerase 1 (PARP1) inhibitors (PARPi)
with high efficiency [20-24].
The PARP family plays important roles in DNA damage
repair. For example, PARP1 is involved in the repair of
DNA single-stranded breaks (SSBs) [25-27]. Inhibition of
PARP1 activity could also result in DSB formation when
unrepaired SSBs meet the replication fork, causing its
collapse. Because BRCA1/2 mutant cells are defective in
repairing DSBs, PARPi inhibition may result in accumu-
lation of DSBs in these cells and eventually lead to apop-
tosis. This may account for the molecular basis of why
BRCA1- and BRCA2-deficient cells are extremely sensitive
to PARPi [20-22]. However, it was shown that several cell
lines derived from mouse BRCA1 mutant mammary can-
cers [28] and a human pancreatic BRCA2 mutant cancer
cell line [29] exhibited resistance to PARPi. While the
exact cause for the resistance was unclear, it was hypothe-
sized that some specific alterations/mutations might block
the sensitivity of these cancer cells to PARPi [30]. It was
subsequently demonstrated that resistance to PARPi could
occur through multiple mechanisms (reviewed in [31]),
such as impaired expression of 53BP1 [32,33], restoration
of BRCA function [34], and induction of P-glycoprotein
expression [35,36]. To overcome the resistance, combin-
ational therapies using multiple chemotherapeutic agents
have been used to enhance the ability to kill BRCA1/2-
related cancers [35,36].
In theory, all clinically used drugs have effects on
biological systems other than those for which they weredesigned; therefore, drug repurposing consists of develop-
ing new applications for existing drugs. There has been an
increase in the interest of drug repurposing due to the
high cost of drug development and time involved in bring-
ing new drugs to the market [16,37]. It has been estimated
that it costs approximately more than USD 800 million to
develop a new drug de novo and the time estimated to
develop a new drug that complies with the regulatory
requirements for safety, efficacy and quality goes in the
order of 10 to 17 years [38].
In this study, a drug repurposing approach using the
National Institutes of Health Chemical Genomics Center
(NCGC) Pharmaceutical Collection (NPC) [39], a library
containing drugs approved for clinical use or that have
been in clinical trials, was used to identify drugs that
amplify the ability of AG14361, a potent PARP1 inhibi-
tor [21], to inhibit the growth of both human and mouse
breast cancer cells, irrespective of their BRCA1 status.
Methods
Cell lines and viral vectors
Our initial study for human cell lines was performed in
three isogenic models derived from the primary cell lines:
92 J, MDA-MB-231 (American Type Culture Collection,
ATCC) and T47D (ATCC) and their BRCA1 mutant
sublines 92 J-sh-BRCA1, MDA-MB-231-sh-BRCA1 and
T47D-sh-BRCA1 respectively. The 92 J cell line, which is
derived from a xenograft tumor of MDA-MB-231, forms
mammary tumors much faster than the parent MDA-MB-
231 cells when implanted into nude mice.
BRCA1 short hairpin RNA (shRNA) constructs in the
pLKO.1-based vector were obtained from Open Biosys-
tems (GE Healthcare, Little Chalfont, UK). A control lenti-
viral shRNA vector, packaging vector pCMV-dR8.2, and
envelope vector VSV-G was obtained from Addgene
(Cambridge, MA, USA). The BRCA1 shRNA construct
(TRCN0000039837) was used to produce lentiviral parti-
cles for generation of stable BRCA1 knockdown cells.
Lentivirus was produced in 293 T cells and the media col-
lected for later transduction of target cells. Cells were
transduced with lentiviral supernatant and then selected
with 2 μg/ml puromycin to generate cells with stable
knockdown of BRCA1. The viral supernatant was used to
infect 92 J, MDA-MB-231 and T47D cells
Mouse BRCA1 mutant cell line 69 derived from mam-
mary tumor of Brca1Co/Co; MMTV-Cre;p53+/− mice con-
taining a targeted deletion of full-length BRCA1 [40]
and BRCA1 wild-type (wt) cell line Ras, derived from
mammary tumor MMTV-Ras mice [41].
Growth assays
For the growth curve assay, 5 × 104 cells were plated per
well of a six-well plate and medium was changed every
24 hr. The plate was incubated at 37°C in 5% CO2 and
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counted with a Z1 Coulter counter (Beckman Coulter,
Brea, CA, USA). Plating for each time point was done in
triplicate for each 92 J isogenic pair. In order to elimin-
ate artifacts that could be produced by the cell line, we
validated the other two pairs of human isogenic cell lines
following the same protocol.
NCGC Pharmaceutical Collection (NPC) and quantitative
high throughput screening
The NPC drug library consists of 2,816 small molecule
compounds at the time of this screening [39]. Fifty-two
percent of the compounds are drugs approved for hu-
man or animal use by the United States Food and
Drug Administration (FDA), 22% are drugs approved
in Europe, Canada or Japan, and the remaining 25%
are drugs approved in other countries or compounds
that have been tested in clinical trials.
For the initial screening, the library was prepared as 15
inter-plate titrations, which were serially diluted 1:2.236 in
dimethyl sulfoxide (DMSO, (Thermo Fisher Scientific,
Waltham, MA, USA) in 384-well plates. The stock con-
centrations of the test compounds ranged from 10 mM to
0.13 μM. Transfer of the diluted compounds from 384-
well plates to 1,536-well plates was performed using an
Evolution P3 system (Perkin Elmer, Wellesley, MA, USA).
Each treatment plate included concurrent DMSO and
positive control wells and concentration-response titrations
of controls, all occupying columns 1 to 4. Cell viability was
measured using a luciferase-coupled ATP quantization
assay of metabolically active cells (ATPliteTM 1step
Luminescence Assay System, Perkin Elmer). Cells were
dispensed at 2,000 cells/5 μL/well in 1,536-well white,
solid-bottom assay plates using a flying reagent dispenser
(FRD). The assay plates were incubated at 37°C for 5 hr to
allow for cell attachment, followed by addition of 5 μl of
compounds via pin tool. After compound addition, plates
were incubated for 48 hr at 37°C. At the end of the incu-
bation period, 5 μL of ATPlite reagent was added, plates
were incubated at room temperature for 20 to 30 min,
and luminescence intensity was determined using a
ViewLux plate reader (Perkin Elmer).
Data analysis
Analysis of compound concentration-response data was
performed as previously described [36]. Briefly, raw plate
reads for each titration point were first normalized relative
to the positive control compound (-100%) and DMSO-
only wells (0%) as follows: % activity = ((Vcompound –
VDMSO)/(Vpos – VDMSO)) × 100, where Vcompound denotes
the compound well value, Vpos denotes the median value
of the positive control wells, and VDMSO denotes the
median values of the DMSO-only wells, and then correc-
ted by applying a NCGC in-house pattern correctionalgorithm using compound-free control plates (DMSO-
only plates) at the beginning and end of the compound
plate stack. Concentration-response titration points for
each compound were fitted to a four-parameter equa-
tion yielding concentrations of half-maximal activity
(AC50) and maximal response (efficacy) values. Compounds
were designated as class 1 to 4 according to the type of
concentration-response curve observed [42,43]. Curve clas-
ses are heuristic measures of data confidence, classifying
concentration-responses on the basis of efficacy, the num-
ber of data points observed above background activity, and
the quality of fit. Compounds with class 1.1, 2.1, 1.2 or 2.2
(>50% efficacy) curves are considered active. Compounds
with class 4 curves are considered inactive and compounds
with all other curves classes are considered inconclusive.
Compounds that were selectively active (showed a potency
difference of >3-fold) in one cell line or with or without the
combination compound were selected for confirmation and
follow-up studies.Determination of synergistic effect and additive effect
The theoretical addictive effect of compounds with
AG14361 was based on the fractional inhibition of these
compounds when used separately. If the 50% inhibition
concentration (IC50) of each drug is administered to-
gether, by the union of two events, the predictive addictive
killing is calculated as Etotal = E1 + E2 – E1 × E2 (where E1
is IC50 of drug 1 and E2 is IC50 of drug 2), which is 75%.
This classifies a drug synergistic if, when treated with the
50% inhibition dose of each drug, the synergistic killing
effect should be significantly greater than 75%.Cell proliferation assays for validation of synergistic effect
In order to validate the synergistic effect of the selected
drugs in vitro we performed cell viability assay using a
luciferase-coupled ATP quantization assay of metabolic-
ally active cells (ATPliteTM 1step Luminescence Assay
System, Perkin Elmer) in a 96-well plate and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT). For MTT, 1 to 2 × 104 cells were plated per
one well of a 24-well plate. Target drugs at various con-
centrations were dissolved in DMSO and then added to
the cells in 10% fetal bovine serum-containing Dulbecco’s
modified Eagle’s medium (DMEM), IC50 concentration of
AG14361 were also added to each well. The final DMSO
concentration was kept at 0.1% after the addition to
medium. After 48 hr medium was removed and 0.3 ml of
0.1% MTT in phosphate-buffered saline (PBS) was added
in each well. After incubation for 30 min in a 37°C CO2
incubator, MTT solution was removed and 0.8 ml of
2-propanol was added. After shaking for 30 min, OD560
was measured using a plate reader. Plating for each time
point was done in triplicate.
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For immunohistochemistry procedures, the tumors
were fixed in phosphate-buffered formalin, embedded
in paraffin, cut in 4-μm thickness, and stained. Immuno-
histochemical analysis of proliferating cell nuclear antigen
(PCNA) was performed using a labeled streptavidin-biotin
technique described previously. Anti-PCNA monoclonal
antibody PC 10 (Dako, Carpenteria, CA, USA), which
reacts exclusively with nuclei, was used at a dilution of
1:200. The number of PCNA-positive cells was counted in
five high-power fields (0.135 mm2 fields at × 200 magnifica-
tion) selected at random, and the PCNA labeling index for
each field was calculated as the percent of PCNA-positive
cells (relative to the total). Apoptosis in tumor cells was
detected using the terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick end-labeling (TUNEL) assay, as
described previously. In the same manner as PCNA, five
fields (0.135 mm2 fields at × 200 magnification) were se-
lected at random, and the apoptotic index of each field
was calculated as the percentage of TUNEL-positive cells.
RT-PCR and real-time PCR
Total RNA from cells or tissues were extracted with
RNA STAT-60™ following the manufacturer’s protocol
(Tel-Test, Inc., Gainesville, FL, USA), and cDNA was
generated by Cells-to-cDNA™II (Ambion, Inc., Austin,
TX, USA). Quantitative RT-PCR was performed using a
SYBR green PCR Master Mix (Applied Biosystems,
Carlsbad, CA, USA) and the 7500 Real-Time PCR system
(Applied Biosystems). Primers used are listed below:
BRCA1F 5′-ctgatgtgctttgttctgga-3′ BRCA1R: 5′-ggctatcct
ctaagagtgaca-3′, β-actinF: 5′gatggagttgaagtgagtttcgtg-3′,
β-actinR 5-gcgggaaatcgtgcgtgcgtgacatt-3′, IL8F: 5′-aat
ctggcaaccctagtctgcta-3′, IL8R: 5′-aaaccaaggcacagtgga
aca-3′, p50F: 5′-cagctcttctcaaagcagca-3′, p50R: 5′tcca
ggtcatagagaggctca-3′, MMP9F: 5′-cctgtgtgttcccgttcatct-3′,
MMP9R: 5′-cgctggaatgatctaagccca-3′, COX2F: 5′-gaagtgg
ggtttaggatcatc-3′, COX2R: 5′-cctttcactttcggataacca-3′,
p65F: 5′-gcaggctcctgtgcgtgtct-3′, p65R: 5′-ggtgctcagggatg
acgtaaag-3′, IL6F: 5′-cactgggcacagaacttatgttg-3′, IL6R:
5′-aaaataattaaaatagtgtcctaacgctcat-3′.
Luciferase reporter assay
The reporter plasmid, pNF-κB-luc, containing the κB-
enhancer consensus sequences ((TGGGGACTTTCC
GC) × 5) and nuclear factor κB (NF-κB)-dependent firefly
luciferase gene was purchased from Stratagene (La Jolla,
CA, USA). 92 J, and MDA-MB-231 isogenic cells were
transiently transfected with two plasmids (pNF-κB-luc
plasmid and renilla) using the LipofectAMINE 2000 Plus
regent. Cells were seeded in a 24-well plate the day prior
to transfection to achieve 80 to 85% confluence on the
following day. Twelve hours after transfection, cells wereincubated for an additional 24 hr in medium containing
IC50 of AG14361, and lestaurtinib as mono-treatment
and in combination and harvested for luciferase reporter
assays. NF-κB transcription activity assay was also
performed in a HeLa cell line, which carries a stably
integrated luciferase reporter (Signosis, Inc., Santa
Clara, CA, USA) after treatment with IC50 of AG14361
and/or lestaurtinib for 24 hr. Luciferase activity was
measured with a luminometer using the Luciferase
Assay System (Signosis). Renilla activity was detected to
normalize any variations.
Caspase 3/7 activity
The 92 J isogenic cell lines were dispensed in culture
medium at 2,000 cells/5 μl/well in 1536-well white/solid-
bottom assay plates. The cells were incubated a minimum
of 5 hr at 37°C. The compounds (23 nl/well) were added
via the pin tool and then Resveratrol or AG14361 were
added. The treated cells were incubated for 5 or 24 hr at
37°C, followed by the addition of the Caspase-Glo 3/7
(Promega, Madison, WI, USA) reagent at 5 μl/well. After
30 min incubation at room temperature, the luminescence
intensity of the assay plates was measured using a View-
Lux Plate Reader (Perkin Elmer).
Cell cycle analysis
After the 12, 24, 36 and 48 hr of drug treatment as
mono-treament and combination, 92 J cells were
trypsinized and washed twice in PBS (pH 7.4). Cells
were fixed in 2 mL 70% ethanol (stored at −20°C),
vigorously vortexed and incubated at 4°C for 4 hr.
The cells were then washed with ice-cold PBS and
resuspended in 200 μl PBS. Subsequently, cell suspen-
sion was incubated with 20 μl DNase-free RNase
(10 mg/mL) and 1 ml of DNA intercalating dye PI
(50 μg/ml, Triton-X 100 1.0%) at 4°C for 30 min. Cell cycle
phase analysis was performed by flow cytometry using
Epics-XL II FACS Caliber flow cytometer (Beckman
Coulter, Brea, CA, USA), and data were analyzed by
Multicycle AV software (Phoenix Flow Systems, San
Diego, CA, USA).
Tumor formation assay in nude mice
Ninety-two J-shBRCA1 and 92 J-PLK cells after trypsini-
zation were resuspended in PBS, the cells were injected
into the fourth mammary fat pad on both sides of female
nude mice at 1 × 106 cells/100 μl/spot. There were four
groups of mice per cell line injected defined by the drug
they were treated by. The first group was injected with
PBS, second group with lestaurnitib, the third with
AG14361, and the fourth with the combination of lestaur-
nitib and AG14361. Each group was formed of seven
mice, with a total of twenty-eight mice per studied cell
line. The drug treatment started when tumors became
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were injected with AG14361 (30 mg/kg) intraperitoneally
five times per week and lestaurtinib (10 mg/kg) three
times per week, respectively. The recipient mice were
housed in pathogen-specific facility, kept in a 12 hr light
and dark cycle, and fed with a regular diet. Mice were
monitored for tumor formation, and were euthanized
when the tumors were 3.5 cm, which required harvesting,
or there were tumor ulcerations. Tumor size was mea-
sured every three days before day 15 and every four days
thereafter with a caliper, and tumor volume was calculated
by using the formula V = 2/3πrxryrz (r is radius and x, y, z
refer to each axis, and π = 3.14). All animal experiments
were approved by the Animal Care and Use Committee of
National Institute of Diabetes, Digestive and Kidney Dis-
eases (ACUC, NIDDK).Statistical analyses
All analyses were performed with the assistance of Graph-
Pad Prism software version 4.0a (GraphPad Software, San
Diego, CA, USA). A P value of less than 0.05 was consid-
ered statistically significant.Results
Isogenic cell lines carrying acute knockdown of BRCA1
expression
In order to screen the NCGC Pharmaceutical Collection
(NPC) Library, we generated three pairs of human iso-
genic cancer cell lines from T47D, MDA-MB-231, and
92 J, which were derived from an xenograft tumor in
nude mice implanted with MDA-MB-231 cells infected
them with lentivirus carrying an shBRCA1 or a control
(PLK) vector. Downregulation of BRCA1 mRNA and
protein were verified by qRT-PCR (Figure 1A), and
Western blot (Figure 1B). We tested levels of prolifera-
tion by MTT (Figure 1C), clonogenic assays (Figure 1D),
and tumor growth (Figure 1E) of these isogenic cell
lines, and found that the 92 J pair (92 J-shBRCA1 and
92 J- wtBRCA1) and MDA-MB-231 pair (MDA-MB-
231-shBRCA1 and MDA-MB-231-wtBRCA1) exhibited
similar growth, irrespective of their BRCA1 status
(Figure 1E). The growth of T47D-shBRCA1 was slower
than that of T47D-wtBRCA1 (Figure 1E), therefore, this
pair of cells was not suitable for drug screening in our fur-
ther experiment. We have also tested two Brca1-deficient
mouse cell lines, 780 and 69, and two Brca1 wild-type cell
lines, NK and Ras, which were derived from mammary
tumors of MMTV-Neu and MMTV-Ras, respectively
[40,41]. The cell lines 69 and Ras showed similar pro-
liferation rate (Additional file 1A), colony formation
(Additional file 1B), and tumor growth in nude mice
(Additional file 1C), therefore they were used for fur-
ther studies.Screening for drugs that synergistically kill breast cancer
cells in the presence of PARP1 inhibitor AG14361
To identify small molecule drugs that can synergize with
PARPi for breast cancer cells, the 92 J isogenic pair of
cell lines was used to screen the NPC library in the
absence or presence of AG14361 at a concentration
that killed 50% (IC50) of cells (92 J-wt-BRCA1, 17 μM,
92 J-sh-BRCA1, 25 μM, respectively). Compounds were
prepared in 15 concentrations with 2.236-fold dilution
titrations in DMSO, with final concentrations ranging
from 0.11 pM to 92 μM. This identified a total of 32
compounds that showed both high potency as mono-
treatment (<30 μM) and had a synergistic effect with
AG14361 (Additional file 2: Table S1). Among these
32 compounds, 17 showed similar levels in killing both
shBRCA1 and wtBRCA1 cells, six were more specific for
killing shBRCA1 cells; and the remaining nine killed
wtBRCA1 cells better.
Next, we focused on 17 compounds that showed simi-
lar levels in killing both shBRCA1 and wtBRCA1 cells.
Confirmation studies were performed with 92 J cells on
a new aliquot of these compounds taken from the ori-
ginal library. Strong synergistic activity was confirmed in
11 of the 17 compounds tested (The first 11 in the Table S1
in Additional file 2). The remaining six compounds, which
showed relatively weak synergy with AG14361 in the ini-
tial screen (Table S1 in Additional file 2), exhibited even
weaker synergy (see Additional file 3).
Lestaurtinib and its combination with AG14361 on breast
cancer cell lines growth in vitro
Among 11 compounds that showed similar levels in killing
both BRCA1 mutant and wild-type cells in the presence of
AG13461, we decided to focus on lestaurtinib (CEP-701)
first. Lestaurtinib is a tyrosine kinase inhibitor and has
been used in several clinical trials for myeloproliferative
disorders and acute myelogenous leukemia [44-46]. In
order to independently verify the activity and synergistic
effect of lestaurtinib with AG14361, we performed ATP
release assay in a 96-well format with lestaurtinib that was
obtained from a different vendor. Besides the 92 J pair of
cell lines, an additional human isogenic pair of breast
cancer cell lines (MDA-MB-231-wtBRCA1 and MDA-
MB-231-shBRCA1), and two mouse mammary cell lines,
Ras and 69, were also used in the assay. The data con-
firmed the synergistic cytotoxic effect of lestaurtinib with
AG14361 in all three pairs of cell lines (Figure 2). We also
performed cell proliferation assays using MTT with a 24-
well format, and obtained similar results (data not shown).
Lestaurtinib and its combination with AG14361 on mouse
breast cancer cell growth in vivo
We compared the responses of mice bearing 92 J-shBRCA1

















































































Figure 1 Human isogenic cell lines proliferation in vitro and tumor growth in xenografts. (A) Reduction in the levels of expression of
BRCA1 in 92 J, MDA-MB-231 and T47D cells transduced with shBRCA1 lentivirus were determined by qRT-PCR and by Western blot analysis. (B)
Western blot analysis showing BRCA1 levels. Immunoblot photographs of three independent experiments were also subjected to densitometry
(right panel). (C) Fold change in cell growth rate in respect of the initial input of cells was measured in human isogenic cell lines. Data shown
represent mean standard deviation (SD) from triplicate experiments. (D) Clonogenic assays performed on the three pair of isogenic cells. A total
of 1,000 cells were seeded in 10 ml plates and grown for 21 days and counted at the end point. Data represent the mean SD from triplicate
experiments. (E) 92 J, MDA-MB-231 and T47D isogenic cells were injected in the mammary fat pad of immunocompromised mice and the tumor
volume was measured when they reached 3.5 mm3. Each experiment group consisted of five mice and each mouse had two tumors. The
measurements on the graph represent the average of ten tumors per group. shBRCA1, sample with short hairpin RNA (shRNA) against breast
cancer type 1 susceptibility (BRCA1).
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ation. For tumors derived from both types of cells, mono-
treatment of AG14361 slightly delayed tumor growth
compared with the vehicle group, and lestaurtinib treat-
ment significantly delayed tumor growth, that took
tumors 30 more days, on average, to reach a similar sizecompared with the tumors in the vehicle-treated group
(Figure 3A,B). Of note, the combination of AG14361
and lestaurtinib resulted in complete tumor regression
in two 92 J-shBRCA1 mice and two 92 J-wtBRCA1 mice
(Figure 3A,B). In these cases, the tumors initiated at about





















































Figure 2 Synergistic effect of lestaurtinib in combination with AG14361 in vitro. Synergistic effect of lestaurtinib in the presence of IC50
AG14361 on 92 J isogenic cell lines (A), MDA-MB-231 isogenic cell lines (B), and 69 and Ras cell lines (C) revealed by ATP release assay. Data
shown represent mean ± standard deviation (SD) from triplicate experiments. IC50, 50% inhibition dose.
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(Figure 3C,D). The growth of the remaining 10 tumors
treated with lestaurtinib/AG14361 was delayed about
20 days compared with tumors with lestaurtinib mono-
treatment. During the treatment, the recipient mice
gradually increased their body weight, which was pro-
portional to the progression of their tumors (Figure 3E,F),
suggesting that the treatment did not cause an adverse ef-
fect on animal health, as measured by weight loss. Thus,
the combined lestaurtinib and AG14361 markedly delayed
tumor growth in all treated mice and even caused
complete regression in four out of fourteen tumors
derived from 92 J-shBRCA1 and 92 J-wtBRCA1 cells,
respectively. Because our data clearly indicate that these
tumors initiated in the beginning and were gradually
regressed later (Figure 3C,D) and such regression was not
observed in the 42 tumors with vehicle, lestaurtinib or
AG14361 mono-treatment derived from each cell line,
we believe the regression is caused by the combinedtreatment of lestaurtinib and AG14361. This suggests
that the combination of lestaurtinib and AG14361
could be useful in a therapeutic setting.
Next, we examined cell proliferation and apoptosis in
tumors of control and drug-treated mice. There was an
increase in TUNEL-positive cells in tumors with an in-
creasing order from no treatment, AG14361, lestaurtinib,
to AG14361/lestaurtinib (Figure 4A,B). The apoptotic
index of the combination therapy reached approximately
90%, which was significantly higher than those from
mice with lestaurtinib (55%), and AG14361 (30%) mono-
treatment, whereas no significant difference between
shBRCA1 and wtBRCA1 tumors was detected (Figure 4B).
Immunochemical staining using an antibody for prolifer-
ating cell nuclear antigen (PCNA) detected a reversed
order of decreasing PCNA-positive cells from these
tumors (Figure 4C,D). Thus, the inhibition of tumor
growth of these treatments is correlated with increased
apoptosis and decreased cell proliferation.
Figure 3 Synergistic effect of lestaurtinib with AG14361 on inhibiting breast cancer tumors in allografts. Tumor progression (A-D) and
body weight of recipient mice (E,F) and all experimental mice. (C,D) show tumor progression in four mice with complete tumor regression upon
the combined treatment of lestaurtinib and AG14361 (indicated as Les + AG* in panels A and B). The day of implantation was designated as day
0 and the drug or vehicle was administered intraperitoneally to nude mice that had developed 92 J-wtBRCA1 and 92 J-shBRCA1 xenograft tumors
of 50- to 100-mm3 volume (about 14 days after cell implantation). shBRCA1, sample with short hairpin RNA (shRNA) against breast cancer type 1
susceptibility (BRCA1); wtBRCA1, sample with wild-type BRCA1 status.
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http://breast-cancer-research.com/content/16/3/R67Treatment results in caspase 3/7 activation and cell cycle
abnormalities
To understand the cause of the enhanced apoptosis, cas-
pase 3/7 activity was measured in the 92 J pair of cells
after treatment with AG14361 and/or lestaurtinib at their
IC50 concentrations. Our data demonstrated that all the
treatments activated caspase 3/7 in a time-dependent
manner. As a mono-treatment, lestaurtinib was a more
potent stimulator of caspase 3/7 activity than AG14361,
and the combination of both drugs significantly enhanced
this activity during the period of treatment of both cell
lines, especially before 36 hr (Figure 5A,B).
Next, we determined the cell cycle distribution of 92 J-
shBRCA1 and 92 J-wtBRCA1 cells after different drug
treatments at four time points using flow cytometry.
The proportion of cells in the G1 phase was markedly
increased upon treatment of AG14361 at 12 hr at theexpense of S and G2 phases as compared to untreated
cells (Figure 5C). From 12 hr to 48 hr, AG14361 treatment
resulted in gradually decreased fraction of cells in the G1
phase and increased in the G2 phase, while a more
dramatic reduction in S phase was observed at 48 hr. This
data is consistent with the finding that AG14361 sig-
nificantly reduced cell proliferation. Compared with un-
treated cells, lestaurtinib at 12 hr did not have an obvious
effect on G1 phase, instead it caused expansion of G2
phase and reduction of S phase. From 12 hr to 48 hr
treatment, lestaurtinib resulted in gradually decreased G1
phase and increased G2 phase, while it did not cause an
obvious change in S phase (Figure 5C). Combined
treatment of AG14361 and lestaurtinib caused further
expansion of cells at G2, which is similar to, but more
severe than the mono-treatment with lestaurtinib. Moreover,















































Figure 4 Analysis of tumors treated with AG14361 and lestaurtinib as mono-treatment and combination therapy. Images (A) and
quantification (B) of TUNEL assay for xenograft tumors from 92 J-shBRCA1 and 92 J-wtBRCA1 cell lines. (C, D) Images (C) and quantification (D)
of PCNA immunochemical staining for the same tumors used in (A, B). Data show the mean of three different readings and are marked by
columns with ± standard deviation (SD) error bars. PCNA, proliferating cell nuclear antigen; shBRCA1, sample with short hairpin RNA (shRNA)
against breast cancer type 1 susceptibility (BRCA1); TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling; wtBRCA1,
sample with wild-type BRCA1 status.
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http://breast-cancer-research.com/content/16/3/R67which is similar to the mono-treatment of AG14361.
Both cell lines showed similar responses (Figure 5D).
Thus the treatment of both drugs recapitulated features
of mono-treatment of these two drugs, consequently
leading to increased apoptosis and inhibition of cell
proliferation.
AG14361 inhibits NF-κB signaling that is enhanced by
lestaurtinib treatment
We previously identified some compounds in this library
that inhibit NF-κB signaling [47]. Among the eleven com-
pounds confirmed in our secondary screen that exhibit
strong synergy with PARPi in killing breast cancers irre-
spective of their BRCA1 status, four can inhibit NF-κB
activity (lestaurtinib, bortezomib, ouabain, and digitoxin).
These data suggest that inhibition of NF-κB might be one
of the reasons for the synergistic killing of these cancercells with PARPi. To investigate this theory, we ana-
lyzed the effect of AG14361 on NF-κB transcriptional
activity using a luciferase reporter. The data showed
that AG14361 treatment inhibited transcriptional activity
of both shBRCA1 and wtBRCA1 cells (Figure 6A). Next,
we investigate the effect of AG14361 on NF-κB signaling
by investigating the expression levels of several down-
stream genes. We found that treatment of AG14361 at its
IC50 significantly repressed expression of all the genes
tested in wtBRCA1 cells; whereas in shBRCA1 cells,
AG14361 could significantly repress expression of IL-6,
IL8, and MMP9, but did not significant change expression
of p65 and COX2 (Figure 6B). These data show that
AG14361 at its IC50 concentration could affect expression
of some transcriptional downstream genes of NF-κB al-
though a stronger effect was observed in wtBRCA1 cells























Figure 5 Caspase 3/7 activity and cell cycle distribution of 92 J isogenic cell lines upon lestaurtinib and/or AG14361 treatment.
(A, B) Percentage of caspase 3/7 activity in 92 J isogenic pair of cells after they were incubated with IC50 of lestaurtinib and/or AG14361 in a
time-dependent manner. (C, D) Distribution of 92 J isogenic pair of cells after they were treated with IC50 of AG14361 and/or lestaurtinib per 12,
24, 36 and 48 hr. There was no difference in the results between the two isogenic cell lines. IC50, 50% inhibition dose.
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NF-κB by AG14361 was potentiated by the presence of
lestaurtinib by examining the expression of a NF-κB lucif-
erase reporter that is stably integrated into the genome of
HeLa cells. The data indicated that while mono-treatment
of AG14361 and lestaurtinib at their IC50 significantly
inhibited the NF-κB transcriptional activity, the combin-
ation of both enhanced the effect (Figure 6C). We then
examined the expression of several downstream genes,
IL-6, IL8, p50, and COX-2. Our data indicated that
lestaurtinib inhibited expression of these genes in a dose-
dependent manner and this effect was significantly
enhanced in the presence of AG14361 at its IC50
concentration (Figure 6D,E, and Additional file 4).
We have also examined the expression of these
genes in the tumors treated with AG14361 and/or
lestaurtinib that were harvested at their end point. The
data indicated that AG14361 mono-treatment had no
obvious effect on IL-6 and COX2 expression, whereas
lestaurtinib significantly inhibited their expression. This
effect was enhanced with the combined treatment with
both drugs (Figure 6F-I).
Discussion
The majority of BRCA1/2-related breast cancers exhibit
high grade and are insensitive to most available hormonal
or targeted therapeutic agents [1-7,48,49]. Moreover many
sporadic breast cancers also exhibit reduced or dimin-
ished expression of BRCA1 [50,51]. Thus the finding that
BRCA1/2-associated breast cancers are highly sensitive toPARPi has been considered as a very promising approach
for breast cancer [20-24,52]. However, like many other
therapeutic agents, PARPi treatment is also associated
with drug resistance after initial response to the treatment
(reviewed in [31]). For example, in phase II trials, 400 mg
twice daily exposure of PARPi olaparib only resulted in
the delay of breast cancer and ovarian cancer progression
(both with median progression-free survival of about six
months), and all patients with BRCA1/2 mutations even-
tually died of cancers [53,54].
In mouse models, prolonged treatment of the PARPi,
AZD2281 also resulted in drug resistance presumably
due to upregulation of Abcb1a/b genes encoding P-
glycoprotein efflux pumps [36]. Do Soto et al. [28] found
that while a PARPi was able to kill naïve BRCA1 mutant
cells with high specificity both in vitro and in vivo, it
exhibited minimal specificity in inhibiting several cell
lines derived from mouse Brca1 mutant mammary
tumors. Altogether, these observations reinforced the
need for screens for additional drugs that efficiently kill
BRCA1/2-associated cancer cells when combined with
PARPi. Of note, it has been demonstrated that PARPi,
when combined with agents that impair DNA repair, are
also effective in killing cancer cells containing wild-type
BRCA1/2 [36,55,56].
In this study, we screened a library that contains 2,816
small molecules, most of which are approved for human
or animal use by the FDA or other countries [39,47], in
the presence of AG14361 at a constant sublethal dose in















































































Figure 6 AG14361 inhibits NF-κB activity and downregulates the levels of expression of NF-κB downstream genes. (A) Luciferase
reporter assay for NF-κB transcription activity after treatment with IC50 of AG14361 for 24 hr in 92 J cell lines. (B) NF-κB transcription activity assay
after treatment with IC50 of AG14361 and/or lestaurtinib for 24 hr in a HeLa cell line, which carries a stably integrated luciferase reporter. (C) The
real-time PCR of five NF-κB downstream genes in 92 J cells. (D, E) Expression of IL6 in 92 J cells in the presence of AG14361 and various concentrations
of lestaurtinib for 24 hr revealed by real-time PCR. (F-H) Expression of IL6 and COX2 in xenograft tumors after treatment of AG14361 and/or lestaurtinib.
Data shown the mean of three different readings and are marked by columns with ± standard deviation (SD) error bars. IC50, 50% inhibition dose;
NF-κB, nuclear factor κB.
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http://breast-cancer-research.com/content/16/3/R67synergistically with PARPi. Our initial screen identified
seventeen compounds that have similar levels in killing
both shBRCA1 and wtBRCA1 cells, six compounds that
are more specific for killing shBRCA1 cells, and nine com-
pounds that kill wtBRCA1 cells better. After validation,
lestaurtinib was selected for further investigation. Lestaur-
tinib is an orally bioavailable multikinase inhibitor for a
number of kinases including protein kinase C-related
kinase 1 (PRK1) [57], FMS-like tyrosine kinase 3 (FLT3)
[44,45], JAK2 [46,58], Trk-A/B/C [59,60]. Lestaurtinib hasbeen used in clinical trials for myeloproliferative disorders,
and acute myelogenous leukemia [44-46], but there has
been no report of its application for breast cancer treat-
ment yet. Our data indicated that lestaurtinib is highly
potent against tumor cells derived from both mouse and
human breast cancers as a mono-treatment agent. In
combination with AG14361, this effect is synergistically
enhanced as reflected by further delay of tumor progres-
sion. We also found that four out of fourteen tumors com-
pletely regressed during combination treatment, while no
Vazquez-Ortiz et al. Breast Cancer Research 2014, 16:R67 Page 12 of 14
http://breast-cancer-research.com/content/16/3/R67regression was observed in the other three groups of mice
(control, mono-treatment of either AG14361 or lestaurti-
nib) carrying a total of 42 tumors derived from each of cell
line tested. Therefore, the synergy between AG14361 and
lestaurtinib treatment is significant in these cancer cells.
The complete tumor regression in these four groups of
animals may reflect a differential threshold response of
these mice to the treatment compared with the other
recipients. In the clinic setting, complete tumor regression
upon the therapeutic treatment is the most desirable
outcome, however it does not always happen. In most
cases, patients display partial response at different degrees,
perhaps, due to individual difference in response to the
treatment [53,54]. Nonetheless, the significant delay of
tumor progression could prolong the life of patients and
provide valuable time for further therapeutic therapies.
Our data are reminiscent of this feature. We are in the
process of screening further drug combinations in order
to achieve the most desirable outcome in the near future.
The effect of lestaurtinib are primarily on G2 arrest,
apoptosis and reduced proliferation of cancer cells
irrespective of their BRCA1 status. Mono-treatment of
AG14361 exhibited a similar, yet mild effect on apoptosis
and proliferation; however, it affected all phases of the cell
cycle. Of note, the combination of both drugs results in
dramatic expansion of cells in the G2 phase at the expense
of the S phase. This may account for the much more se-
vere growth retardation and markedly enhanced cell
death. Of note, we found that four out of eleven com-
pounds, including lestaurtinib, which exhibits synergy
with PARPi, could inhibit NF-κB activity based on our
previous study [47]. NF-κB is a transcription factor that
plays important roles in cell cycle progression, cell survival
and inflammation [1,52,59,60]. Therefore we tested the
effect of AG14361 on NF-κB and found it could also in-
hibit NF-κB activity, albeit to a less extent compared with
lestaurtinib. When combined together, AG14361 and les-
taurtinib exhibited a much stronger inhibitory effect on the
expression of a number of genes in the NF-κB signaling
pathway, such as p50, p65, IL6, IL8, COX2 and MMP9 that
are involved in cancer cell proliferation, inflammation,
invasion and/or cell death [45,50,54,58,59].
Conclusions
Our data indicated that lestaurtinib is a potent thera-
peutic agent for killing breast cancer cells and it amp-
lifies the ability of the PARP1 inhibitor AG14361 to
kill breast cancer cells irrespective to their BRCA1
status. This effect is, at least in part, by inhibiting
NF-κB signaling. Because lestaurtinib and PARPi are
drugs approved for clinical trials for several different
cancers [44-46,53,54], we believe this combination will
be applicable for a breast cancer trial in the near
future.Additional files
Additional file 1: Murine cell lines Ras and 69 proliferation in vitro
and tumor growth in allografts. (A) Fold change in the cell growth
rate in respect to the initial inoculated Ras and 69 cells lines. Data shown
represent mean standard deviation (SD) from triplicate experiments. (B)
Example of clonogenic assay performed on Ras and 69 cell lines. A total
of 1,000 cells were seeded in 10 ml plates and grown for 21 days and
counted at the end point. Data represent the mean SD from triplicate
experiments. (C) Cells were injected into the mammary fat pad of nude
mice and the tumor volume was measured until they reached 3.5 mm3.
Each group consisted of five mice and each mouse had two tumors,
the measurements on the graph represent the average of ten tumors
per group.
Additional file 2: Table S1. Identification of clinically used drugs that
kill 92 J isogenic pair as single agents and show the synergistic toxic
effect with AG14361.
Additional file 3: Cell viability assay of deserpiline that was
eliminated for further analysis after the cherry pick. (A) Viability assay
of deserpiline from the primary high throughput screen. (B) Viability
assay of the same drug from the secondary screen. The synergy is less
obvious in the secondary screen as some points of the curve touch, or
even cross with the expected additive values curve.
Additional file 4: Synergistic effect of lestaurtinib in combination
with AG14361 in Ras and 69 cell lines. Expression of COX2 (A,B),
IL8 (C,D), and p50 (E,F) in 92 J pair of isogenic cells in the presence of
AG14361 and/or various concentrations of lestaurnitib for 24 hr revealed
by real-time PCR. Data show the mean of three different readings and
are marked by columns with ± standard deviation (SD) error bars.
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